Pharmafile Logo

News and Press Releases

Touchlight Awarded Tender to Supply Enzymatic dbDNA to CPI’s RNA Centre of Excellence

28 March 2024 -- Hampton, UK -- Touchlight, an innovation-driven CDMO enabling the development of genetic medicines with its doggybone DNA (dbDNA) technology and leaders in enzymatic DNA production, is...

Category: Biotechnology
Posted: March 28, 2024

Touchlight
info@touchlight.com
Morelands & Riverdale Buildings Lower Sunbury Road Hampton TW12 2ER

Jemperli (dostarlimab) becomes the first immunotherapy treatment to receive NICE recommendation for use, in line with its license, in eligible endometrial cancer patients in first line setting

This final draft guidance recommends the use of dostarlimab in combination with platinum-containing chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or...

Category: Clinical Trials, Drug Discovery
Posted: March 5, 2024

GSK
980 Great West Rd, London TW8 9GS

Real-World Evidence Demonstrates Feasibility and Safety of Outpatient Administration of Yescarta (axicabtagene ciloleucel)

Findings show comparable safety for patients administered axicabtagene ciloleucel in the outpatient setting in the US to inpatient infusion  Real-world evidence supports further exploration of use of outpatient administration of...

Category: Clinical Trials
Posted: February 15, 2024

Kite Pharma
2400 Broadway Santa Monica, CA 90404

NICE has issued guidance for GSK’s Omjjara (momelotinib) as a treatment option for disease-related splenomegaly or symptoms in adult myelofibrosis patients with moderate to severe anaemia

Myelofibrosis is a rare blood cancer that can result in the progressive scarring of bone marrow (fibrosis), impairing its normal function There are approximately 1,970 people living with myelofibrosis across...

Category: Clinical Trials
Posted: February 15, 2024

GSK
980 Great West Rd, London TW8 9GS

Medicines and Healthcare Products Regulatory Agencyauthorises GSK’s Omjjara (momelotinib) in Great Britainfor treating splenomegaly or symptoms in adultmyelofibrosis patients with moderate to severe anaemia

First JAK inhibitor treatment in Great Britain specifically indicated for both newly diagnosed and previously treated myelofibrosis patients with moderate to severe anaemia 31 January 2024 -- Middlesex, UK --...

Category: Pharmaceutical
Posted: January 31, 2024

GSK
980 Great West Rd, London TW8 9GS